InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF) is working towards flexibly shifting from production of one cannabinoid to a variety of them. To accomplish this, the company has reached out to contract development and manufacturing organizations for collaboration. It is enthusiastic about developing treatments, which can address the medical needs of a majority of diseases.
The Company Has Engaged a New Approach to Produce Pharmaceutical-Grade Cannabinoids
InMed has a special interest in the therapeutic potential of cannabinoids. The current method of obtaining cannabinoids is to grow, harvest extract, and purification. However, this is not a long-term methodology for meeting the pharmaceutical demand. A synthetic process, which offers reliability, is consistent and scalable is necessary.
The clinical-stage pharmaceutical company has established a new approach likely to meet this demand; IntegraSyn. In collaboration with drug manufacturing experts, the company will be developing the integrated manufacturing system, which will boost the production of competitively-priced and pharmaceutical-grade cannabinoids.
The systems are flexible and engage in various pharmaceutical manufacturing processes. The starting point is a bacterial-based fermentation step, which generates a branded and high-efficiency enzyme in big numbers. Among other steps, the final process is the cannabinoid assembly of standard purification through the use of standard purification equipment. The end product is then used either for pharmaceutical R&D or direct commercialization.
The Goals of Integrasyn Vary
The IntegraSyn process is not only flexible but also cost-effective. It is suitable for long term needs and could be the solution for a wide range of bio-identical cannabinoids. There are unique goals attached to this process, including the need to escalate earnings beyond traditional biosynthesis and reduce costs by avoiding expensive manufacturing steps.
The process should also be able to help in meeting the market demand for cannabinoids. Who knows? The rare cannabinoids may turn out to be the most promising treatment options.
With the presence of over 100 rare cannabinoids in just trace amounts in the Cannabis plant, InMed says that the pharmaceutical industry has a bright future. Meanwhile, the company is working on two programs in dermatological and ocular diseases. They are INM-088 for treating glaucoma and INM-755 cannabinol (CBN) cream for epidermolysis bullosa.
 Presents Details of Integrasyn, the Company’s New Approach to Producing Pharmaceutical-Grade Cannabinoids){kind=link}